Involving natural food ingredients in controlling blood glucose in diabetic patients has been widely studied. However, there is little information about the effect of the ingredients on improvement of clinical, laboratory, and gut function markers.
OBJECTIVE:
This study was aimed to examine the effect of Job’s tears-enriched yoghurt on weight, fasting blood glucose, GLP-1, and Calprotectin in patients with type 2 Diabetes Mellitus.
METHODS:
Sixty male and female subjects with T2DM participating in this study were divided in two groups; received yoghurt (control group/C) and Job’s tears-enriched yoghurt (treatment group/T). Subjects use metformin only were allowed. Job’s tears seed was extracted using a standard process. Height and weight were measured. Laboratory examination for fasting blood glucose, GLP-1, and calprotectin were performed using standard methods. Appropiate statistical analysis tests were applied to examine variables change within and between groups. Significancy was set at p <0.05.
Get full access to this article
View all access options for this article.
References
1.
PudduA, SanguinetiR, MontecuccoF, VivianiGL. Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes. Mediators Inflamm. 2014;162021. doi:
10.1155/2014/162021.
2.
CrommenS, SimonMC. Microbial regulation of glucose metabolism and insulin resistance. Genes. 2018;9(1): 10; doi:
10.3390/genes9010010.
3.
HeM, ShiB. Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci. 2017;7:54. doi:
10.1186/s13578-017-0183-1.
4.
YadavH, LeeJH, LloydJ, WalterP, RaneSG. Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion. J Biol Chem. 2013;288(35): 25088–97. doi:
10.1074/jbc.M113.452516.
5.
TazoeH, OtomoY, KarakiS, KatoI, FukamiY, TerasakiM, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed Res. 2009;30(3): 149–56.
6.
KarakiS, TazoeH, HayashiH, KashiwabaraH, TooyamaK, SuzukiY, et al. Expression of the short-chain fatty acid receptor GPR43 in the human colon. J Mol Histol. 2008;39(2): 135–42.
7.
ByrneCS, ChambersES, MorrisonDJ, FrostG. The role of short chain fatty acids in appetite regulation and energy homeostasis. Int J Obesity. 2015;39:1331–38.
8.
LarsenMP, TorekovSS. Review article. Glucagon-like peptide 1: A predictor of type 2 diabetes?J Diabetes Res. 2017;7583506. doi:
10.1155/2017/7583506.
9.
DammsA, BischoffSC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis. 2008;23:985–92.
10.
BischoffSC, BarbaraG, BuurmanW, OckhuizenT, SchulzkeJD, SerinoM. Intestinal permeability: A new target for disease prevention and therapy. Gastroenterology. 2014;14:189. doi:
10.1186/s12876-014-0189-7.
11.
GalloA, GasbarriniA, PassaroG, LandolfiR, MontaltoM. Role of fecal calprotectin in monitoringresponse to therapy in inflammatory bowel diseases. J Clin Cell Immunol. 2014;5:1–6.
12.
LarsenN, VogensenFK, van den bergFJ, NielsenDS, AndreasenAS, PedersenBK, et al. Gut microbiota in human adults with type2 diabetes differs from non-diabetic adults. Plos One. 2010;5:e9085.
13.
AllinKH, NielsenT, PedersenO. Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2015;172(4): R167–77. doi:
10.1530/EJE-14-0874.
14.
DumasAA, LapointeA, DugrenierM, ProvencherV, LamarcheB, DesrochesS. A systematic review of the effect of yoghurt consumption on chronic diseases risk markers in adults. Eur J Nutr. 2017;56(4): 1375–92. doi:
10.1007/s00394-016-1341-7.
15.
CaniPD, BibiloniR, KnaufC, WagetA, NeyrinckAM, DelzenneNM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.
16.
GomesAC, BuenoAA, de SouzaRGM, MotaJF. Gut microbiota, probiotics and diabetes. Nutr J. 2014;13(1): 60.
10.1186/1475-2891-13-60.
17.
RoberfroidM, GibsonGR, HoylesL, McCartneyAL, RastallR, RowlandI, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr. 2010;104:S1–63.
18.
CoviànDR, MadiedoPR, MargollesA, GueimondeM, GavilànCGR, SalazarN. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016;7:185. doi:
10.3389/fmicb.2016.00185.
19.
HiraT, SutoR, KishimotoY, KanahoriS, HaraH. Resistant maltodextrin or fructooligosaccharides promotes GLP-1 production in male rats fed a high-fat and high-sucrose diet, and partially reduces energy intake and adiposity. Eur J Nutr. 2018;57(3): 965–79. doi: 10.1007/s00394-017-1381-7.
20.
American Diabetes Association.Diagnosis and Classification of Diabetes Mellitus. Position Statement. Diabetes Care2014Jan;37(Supplement 1): S81–S90.
21.
ZemelMB, RichardsJ, MathisS, MilsteadA, GebhardL, SilvaE. Dairy augmentation of total and central fat loss in obese subjects. Int J Obes. 2005;29(4): 391–7.
22.
ZhangQ, WuY, FeiX. Effects of probiotics on glucose metabolism in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Medicina (Mex). 2016;52(1): 28–34.
23.
ShakenH, HadaeghH, AbediF, Tajabadi-EbrahimiM, MazroiiN, GhandiY, eal. Consumption of synbiotic bread decreases triacylglycerol and VLDL levels while increasing HDL levels in serum from patients with type-2 diabetes. Lipids. 2014;49:695–701.
24.
SilkD, DavisA, VulevicJ, TzortzisG, GibsonG. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2009;29:508–18.
25.
VollmerK, HolstJJ, BallerB, EllrichmanM, NauckMA, SchmidtWE, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic, glucose tolerance. Diabetes. 2008;57(3): 678–87.
26.
CaniPD, LecourtE, DewulfEM, SohetFM, PachikianBD, NaslainD, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am J Clin Nutr. 2009;90(5): 1236–43.
27.
Gil-LozanoM, MingomatajEL, WuWK, RidoutSA, BrubakerPL. Circadian secretion of the intestinal hormone GLP-1 by the rodent L cells. Diabetes. 2014;63(11): 3674–85.
28.
MuñozJSG, RodríguezDJ, MoranteJJH. Diurnal rhythms of plasma GLP-1 levels in normal and overweight/obese subjects: lack of effect of weight loss. J Physiol Biochemistry. 2015;71(1): 17–28.
29.
HalmosEP, ChristophersenCT, BirdAR, ShepherdSJ, MuirJG, GibsonPR. Consistent prebiotic effect on gut microbiota with altered FODMAP intake in patients with Crohn's disease: a randomized controlled cross-over trial of well-defned diets. Clin Transl Gastroenterol. 2016;7(4): e164.
30.
MalcomsonFC, WillisN, McCallumI, XieL, LagerwaardB, KellyS, et al. Non-digestible carbohydrates supplementation increases miR-32 expression in the healthy human colorectal epithelium: a rendomized controlled trial. Mol Carcinog. 2017;56(9): 2104–11. doi: 10.1002/mc.22666.
31.
HesterN, MastaloudisA, GrayR, EvansM, WoodS. Anthocyanin and prebiotic impact on intestinal environment in obese male and female subjects. FASEB. 2017;31:lb11091.2.
32.
CasellasF, BorruelN, TorrejoNA, VarelaE, AntolinM, GuarnerF, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowerd fecal calprotectin. Aliment Pharmacol Ther. 2007;25(9):1061–7.
